ストックスクリーナーアプリを入手
0.0294
0.86%
-0.0171
アフターアワーズ：
.03
0.0006
+2.04%
Galera Therapeutics Inc (GRTX) 最新ニュース
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times
Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics extends agreement deadline - Investing.com Australia
Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com
Galera Therapeutics holds annual stockholder meeting By Investing.com - Investing.com South Africa
Galera Therapeutics holds annual stockholder meeting - Investing.com India
Oral Mucositis Market to Expand Significantly by 2034, States DelveInsight Report - EIN News
Galera Therapeutics Acquires Nova Pharmaceuticals to Advance Breast Cancer Treatment - MSN
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MyChesCo
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Galera Therapeutics director Nancy Chang buys $499,978 in stock By Investing.com - Investing.com South Africa
St. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics director Nancy Chang buys $499,978 in stock - Investing.com
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition - TipRanks
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - GlobeNewswire
Galera Therapeutics Acquires Nova Pharma, Pivots to Breast Cancer Drug Development with $3M Investment - StockTitan
Galera Therapeutics, Inc. acquired Nova Pharmaceuticals, Inc. - Marketscreener.com
Guardian Capital Partners Acquires Team LINX to Drive Growth in Technology Infrastructure - MyChesCo
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA.Today
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MyChesCo
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
The 2024 Biotech Graveyard - Fierce Biotech
Galera stockholders reject liquidation plan - Investing.com
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MyChesCo
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire
Radiotherapy Induced Oral Mucositis Treatment Market, 2032 - Global Market Insights
Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - GlobeNewswire
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - TradingView
Charah Solutions acquires Cheswick Generating Station, related facilities from GenOn - Pennsylvania Business Report
Travere downsizes after a failed bid for sparsentan label expansion - Pharmaceutical Technology
Candel downsizes to focus on oncolytic virus-based cancer therapies - Clinical Trials Arena
GALERA THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) - marketscreener.com
Galera Therapeutics (NASDAQ: GRTX) up 22%last chance saloon here, really - Dhaka Tribune
Galera stock downgraded at BofA on FDA snub (NASDAQ:GRTX) - Seeking Alpha
FDA Issues CRL for Avasopasem for Severe Mucositis in Head & Neck Cancer - CancerNetwork
10 Approvals To Look Out For In Q3 2023 - insights.citeline.com
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting - GlobeNewswire
Contract Suit Alleges Drug Developer Improperly Analyzed Clinical Trial Data - law.com
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer - Yahoo 財經
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):